ESR1 and breast neoplasm: After intraperitoneal injections at low concentration (1.5 mg/kg, three times a week for four weeks), this peptide decreases by ~50% the size of ERα-related human breast tumors (MDA-MB-231 breast cancer cells) xenografted in nude mice [35].